MX2022002022A - Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones. - Google Patents
Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones.Info
- Publication number
- MX2022002022A MX2022002022A MX2022002022A MX2022002022A MX2022002022A MX 2022002022 A MX2022002022 A MX 2022002022A MX 2022002022 A MX2022002022 A MX 2022002022A MX 2022002022 A MX2022002022 A MX 2022002022A MX 2022002022 A MX2022002022 A MX 2022002022A
- Authority
- MX
- Mexico
- Prior art keywords
- conditions
- prophylaxis
- treatment
- formula
- muscle
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 210000003205 muscle Anatomy 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000002699 waste material Substances 0.000 title 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 2
- 201000000585 muscular atrophy Diseases 0.000 abstract 2
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 201000009623 Myopathy Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19192107 | 2019-08-16 | ||
| PCT/EP2020/072911 WO2021032643A1 (en) | 2019-08-16 | 2020-08-14 | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002022A true MX2022002022A (es) | 2022-05-11 |
Family
ID=67659191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002022A MX2022002022A (es) | 2019-08-16 | 2020-08-14 | Compuestos adecuados para el tratamiento y la profilaxis del desgaste muscular y otras afecciones. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12331042B2 (enExample) |
| EP (1) | EP4013497B1 (enExample) |
| JP (1) | JP2022544803A (enExample) |
| KR (1) | KR20220047807A (enExample) |
| CN (1) | CN114302881B (enExample) |
| AU (1) | AU2020334194A1 (enExample) |
| BR (1) | BR112022002769A2 (enExample) |
| CA (1) | CA3144700A1 (enExample) |
| CL (1) | CL2022000320A1 (enExample) |
| IL (1) | IL290540A (enExample) |
| MX (1) | MX2022002022A (enExample) |
| WO (1) | WO2021032643A1 (enExample) |
| ZA (1) | ZA202202863B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102823820B1 (ko) * | 2022-09-01 | 2025-06-23 | 단국대학교 천안캠퍼스 산학협력단 | 퓨로크로멘온계 화합물을 유효성분으로 포함하는 근감소증 예방 또는 치료용 약학 조성물 |
| WO2024068809A1 (en) * | 2022-09-30 | 2024-04-04 | Société des Produits Nestlé S.A. | Composition and method for treating muscle decline associated with renal disease or dysfunction |
| KR102995500B1 (ko) * | 2024-11-07 | 2026-07-23 | 아주대학교산학협력단 | 근감소증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200803016B (en) * | 2005-09-29 | 2009-10-28 | Elan Pharmaceuticals Inc Wyeth | Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| EP2072528A1 (en) | 2007-12-19 | 2009-06-24 | Labeit, Mr. Siegfried | A host cell deficient for MuRF1 and MuRF2 |
| US20140161729A1 (en) * | 2011-04-07 | 2014-06-12 | Cornell University | Cofluorons and methods of making and using them |
| CN106822153B (zh) * | 2011-06-06 | 2019-12-17 | 爱荷华大学研究基金会 | 用于抑制肌萎缩的方法 |
| AU2014290368B2 (en) * | 2013-07-18 | 2019-07-11 | Baylor College Of Medicine | Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia |
| WO2015050984A1 (en) * | 2013-10-01 | 2015-04-09 | New York University | Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof |
| CN112274183A (zh) * | 2020-11-02 | 2021-01-29 | 李云莹 | 一种神经内科用脑部超声波治疗装置 |
-
2020
- 2020-08-14 CN CN202080057706.5A patent/CN114302881B/zh active Active
- 2020-08-14 EP EP20764952.6A patent/EP4013497B1/en active Active
- 2020-08-14 CA CA3144700A patent/CA3144700A1/en active Pending
- 2020-08-14 US US17/634,174 patent/US12331042B2/en active Active
- 2020-08-14 BR BR112022002769A patent/BR112022002769A2/pt not_active Application Discontinuation
- 2020-08-14 WO PCT/EP2020/072911 patent/WO2021032643A1/en not_active Ceased
- 2020-08-14 AU AU2020334194A patent/AU2020334194A1/en not_active Abandoned
- 2020-08-14 MX MX2022002022A patent/MX2022002022A/es unknown
- 2020-08-14 JP JP2022510087A patent/JP2022544803A/ja active Pending
- 2020-08-14 KR KR1020227007940A patent/KR20220047807A/ko not_active Ceased
-
2022
- 2022-02-08 CL CL2022000320A patent/CL2022000320A1/es unknown
- 2022-02-10 IL IL290540A patent/IL290540A/en unknown
- 2022-03-09 ZA ZA2022/02863A patent/ZA202202863B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202202863B (en) | 2023-10-25 |
| EP4013497A1 (en) | 2022-06-22 |
| JP2022544803A (ja) | 2022-10-21 |
| WO2021032643A1 (en) | 2021-02-25 |
| AU2020334194A1 (en) | 2022-02-24 |
| CA3144700A1 (en) | 2021-02-25 |
| US12331042B2 (en) | 2025-06-17 |
| CN114302881A (zh) | 2022-04-08 |
| KR20220047807A (ko) | 2022-04-19 |
| EP4013497C0 (en) | 2023-10-04 |
| BR112022002769A2 (pt) | 2022-05-10 |
| US20220324852A1 (en) | 2022-10-13 |
| EP4013497B1 (en) | 2023-10-04 |
| IL290540A (en) | 2022-04-01 |
| CL2022000320A1 (es) | 2023-02-03 |
| CN114302881B (zh) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22019360A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| ZA202202863B (en) | Compounds suitable for the treatment and prophylaxis of muscle wasting and other conditions | |
| MX384868B (es) | Composiciones para tratar atrofia muscular espinal. | |
| MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| MX388641B (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| CO2020014677A2 (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| BR112017017275A2 (pt) | composto, composição farmacêutica, método para o tratamento e uso do composto | |
| MX388378B (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| MX2026000031A (es) | Atrofia muscular | |
| MX392555B (es) | Composiciones y métodos para el tratamiento de resistencia a la insulina. | |
| ECSP23027106A (es) | Formulación combinada oral que incluye gemigliptina y dapagliflozina y método de preparación para la misma | |
| MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors |